Veille bibliographique COVID-19 et maladies du globule rouge

Partager sur :

L’équipe projet de la filière vous propose une veille bibliographique spécifique COVID-19 et maladies du globule rouge. Les articles proposés sont pour la plupart des « preprints » acceptés dans des journaux référencés dans PubMed. Ils sont classés par maladie, puis par date de publication.

Ces articles sont recensés à titre d’information et n’indiquent aucunement un cautionnement de leur contenu par la filière. La qualité et la pertinence de leur contenu et des conclusions restent à l’appréciation des lecteurs. 

Dernière modification : 29 juillet 2020.

Hémoglobinopathies – Pathologies associées du globule rouge

  • Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic. Roy NB, Telfer P, Eleftheriou P, et al. Br J Haematol. [published online ahead of print, 2020 Apr 24]. doi: 10.1111/bjh.16687
  • Care of patients with hemoglobin disorders during the COVID-19 pandemic: an overview of recommendations. Taher AT, Bou-Fakhredin R, Kreidieh F, Motta I, De Franceschi L, Cappellini MD. Am J Hematol. [published online ahead of print, 2020 May 11]. doi: 10.1002/ajh.25857
  • Rare anaemias, sickle cell disease and COVID-19. Vives Corrons JL, De Sanctis V. Acta Biomed. 2020 May 11;91(2):216-217. doi: 10.23750/abm.v91i2.9532
  • Management of hemoglobin disorders during the COVID-19 pandemic. Chowdhury SF, Anwar S. Front Med (Lausanne). 2020 Jun 9;7:306. doi: 10.3389/fmed.2020.00306
  • Preliminary data on COVID-19 in patients with hemoglobinopathies: a multicentre ICET-A study. de Sanctis V, Canatan D, Corrons JLV, et al. Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020046. doi: 10.4084/MJHID.2020.046
  • A case of COVID-19 in a patient with asymptomatic hemoglobin D thalassemia and glucose-6-phosphate dehydrogenase deficiency. Sasi S, Yassin MA, Nair AP, Al Maslamani MS. Am J Case Rep. 2020 Jul 22;21:e925788. doi: 10.12659/AJCR.925788

Déficit en glucose-6-phosphate déshydrogénase (déficit en G6PD)

  • G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? Kassi EN, Papavassiliou KA, Papavassiliou AG. J Cell Mol Med. [published online ahead of print, 2020 Apr 12]. doi: 10.1111/jcmm.15312
  • Is glucose-6-phosphate dehydrogenase enzyme deficiency a factor in Coronavirus-19 (COVID-19) infections and deaths? Aydemir D, Ulusu NN. Pathog Glob Health 2020 May;114(3):109-110. Epub 2020 Apr 14:1-2. doi: 10.1080/20477724.2020.1751388
  • G6PD deficiency in COVID-19 pandemic: “A ghost in the ghost”. Al-Abdi S, Al-Aamri M. Hematol Oncol Stem Cell Ther. [published online ahead of print, 2020 Apr 18]. doi: 10.1016/j.hemonc.2020.04.002
  • Acute hemolysis by hydroxychloroquine was observed in G6PD-deficient patient with severe COVID-19 related lung injury. De Franceschi L, Costa E, Dima F, Morandia M, Olivieri O. Eur J Intern Med. [published online ahead of print, 2020 Apr 20]. doi: 10.1016/j.ejim.2020.04.020
  • COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose‐6‐phosphate dehydrogenase deficiency. Beauverd Y, Adam Y, Assouline B, Samii K. Eur J Haematol. [published online ahead of print, 2020 Apr 23]. doi: 10.1111/EJH.13432
  • The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Capoluongo ED, Amato F, Castaldo G. Clin Chem Lab Med. [published online ahead of print, 2020 Apr 24]. doi: 10.1515/cclm-2020-0442
  • G6PD deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine. Kuipers MT, van Zwieten R, Heijmans J, et al. Am J Hematol. [published online ahead of print, 2020 May 10]. doi: 10.1002/ajh.25862
  • Why G6PD deficiency should be screened before COVID-19 treatment with hydroxychloroquine? Oymak Y, Karapinar TH, Devrim İ. J Pediatr Hematol Oncol. [published online ahead of print, 2020 June 2]. doi: 10.1097/MPH.0000000000001864
  • A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine. Maillart E, Leemans S, Van Noten H, et al. Infect Dis (Lond). [published online ahead of print, 2020 June 4]. doi: 10.1080/23744235.2020.1774644
  • Doubtful precipitation of hemolysis by hydroxychloroquine in glucose‐6‐phosphate dehydrogenase deficient patient with COVID‐19 infection. Afra TP, Vasudevan Nampoothiri R, Razmi T M. Eur J Haematol. [published online ahead of print, 2020 June 5]. doi: 10.1111/EJH.13460
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency and COVID-19 infection. Vick DJ. Mayo Clin Proc. [published online ahead of print, 2020 June 6]. doi: 10.1016/j.mayocp.2020.05.035
  • Glucose 6 phosphate dehydrogenase deficiency: an actionable risk factor for patients with COVID-19? Jamerson B, Haryadi T, Bohannon A. Arch Med Res. [published online ahead of print, 2020 June 7]. doi: 10.1016/j.ejim.2020.04.020
  • Methemoglobinemia in patient with G6PD deficiency and SARS-CoV-2 infection. Palmer K, Dick J, French W, Floro L, Ford M. Emerg Infect Dis. 2020 Sep. [published online ahead of print, 2020 June 24]. doi: 10.3201/eid2609.202353
  • Linking hydroxychloroquine to hemolysis in a ‘suspected’ glucose-6-phosphate dehydrogenase deficient patient with COVID-19 infection – a critical appraisal. Afra TP, Vasudevan Nampoothiri R, Razmi T M, Bishurul Hafi NA. Eur J Intern Med. [published online ahead of print, 2020 July 7]. doi: 10.1016/j.ejim.2020.07.001
  • Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous n-acetylcysteine. Ibrahim H, Perl A, Smith D, et al. Clin Immunol. [published online ahead of print, 2020 July 22]. doi: 10.1016/j.clim.2020.108544

Drépanocytose

  • COVID-19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Beerkens F, John M, Puliafito B, Corbett V, Edwards C, Tremblay D. Am J Hematol. [published online ahead of print, 2020 Apr 3]. doi: 10.1002/ajh.25809
  • Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19). Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Am J Hematol. [published online ahead of print, 2020 Apr 8]. doi: 10.1002/ajh.25821
  • Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. De Luna G, Habibi A, Deux JF, et al. Am J Hematol. [published online ahead of print, 2020 Apr 13]. doi: 10.1002/ajh.25833
  • Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic. DeBaun MR. Blood [published online ahead of print, 2020 Apr 13]. doi: 10.1182/blood.2020005992
  • COVID‐19 infection in patients with sickle cell disease. Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. Br J Haematol. [published online ahead of print, 2020 Apr 21]. doi: 10.1111/bjh.16734
  • Mitigating the effect of the COVID-19 pandemic on sickle cell disease services in African countries. Dexter D, Simons D, Kiyaga C, et al. Lancet Haematol. [published online ahead of print, 2020 Apr 23]. doi: 10.1016/S2352-3026(20)30122-8
  • Dramatic improvement after Tocilizumab of a severe COVID-19 in a child with sickle cell disease and acute chest syndrome. Odièvre MH, de Marcellus C, Ducou, et al. Am J Hematol. [published online ahead of print,  2020 May 1]. doi: 10.1002/ajh.25855
  • COVID-19 infection and sickle cell disease: a UK centre experience. McCloskey KA, Meenan J, Hall R, Tsitsikas DA. Br J Haematol. [published online ahead of print, 2020 May 5]. doi: 10.1111/bjh.16779
  • Combination dose-escalated hydroxyurea and transfusion: an approach to conserve blood during the COVID-19 pandemic. Nickel RS, Margulies S, Frazer B, Luban NLC, Webb J. Blood [published online ahead of print, 2020 May 13]. doi: 10.1182/blood.2020006582
  • Patients with sickle cell disease and suspected COVID‐19 in a pediatric ICU. Heilbronner C, Berteloot L, Tremolieres P, et al. Br J Haematol. [published online ahead of print, 2020 May 18]. doi: 10.1111/bjh.16802
  • Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience. Sahu KK, Siddiqui AD, Cerny J. Br J Haematol. [published online ahead of print, 2020 May 23]. doi: 10.1111/bjh.16880
  • [Commentaire sur l’article DeBaun MR., Initiating adjunct low dose-hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic, mis en ligne le 13 avril et cité ci-dessus] COVID-19 and SCA: an old friend comes to the rescue. Novelli EM. Blood, 2020 May 28;135(22):1925-1926. doi: 10.1182/blood.2020006442
  • COVID-19 in patients with sickle cell disease – a case series from a UK Tertiary Hospital. Chakravorty S, Padmore-Payne G, Ike F, et al. Haematologica. [published online ahead of print, 2020 June 11]. doi: 10.3324/haematol.2020.254250
  • COVID-19 as a trigger of Acute Chest Syndrome in a pregnant woman with Sickle Cell Anemia. Justino CC, Campanharo FF, Augusto MN, Cezarino de Morais S, Figueiredo MS. Hematol Transfus Cell Ther. [published online ahead of print, 2020 June 18]. doi: 10.1016/j.htct.2020.06.003
  • Prognosis of patients with sickle cell disease and COVID-19: a French experience. Arlet JB, de Luna G, Khimoud D, et al. Lancet Haematol. [published online ahead of print, 2020 June 18]. doi: 10.1016/S2352-3026(20)30204-0
  • Sickle cell trait and the potential risk of severe coronavirus disease 2019 – A mini-review. Kehinde TA, Osundiji MA. Eur J Haematol. [published online ahead of print, 2020 June 26]. doi: 10.1111/ejh.13478
  • Clinical management of a Nigerian patient affected by sickle cell disease with rare blood group and persistent SARS‐CoV‐2 positivity. Quaresima M, Quaresima V, Naldini MM, et al. eJHaem. 2020:1-4. [published online ahead of print, 2020 July 4]. doi: 10.1002/jha2.53
  • Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease? Allison D, Campbell-Lee S, Crane J, et al. J Clin Apher. [published online ahead of print, 2020 July 6]. doi: 10.1002/jca.21809
  • Coronavirus disease among persons with sickle cell disease, United States, March 20–May 21, 2020. Panepinto JA, Brandow A, Mucalo L, et al. Emerg Infect Dis. 2020 Oct. [published online ahead of print, 2020 July 8]. doi: 10.3201/eid2610.202792
  • A Saudi family with sickle cell disease presented with acute crises and COVID‐19 infection. Al-Hebshi A, Zolaly M, Alshengeti A, et al. Pediatr Blood Cancer. 2020;e28547. [published online ahead of print, 2020 July 10]. doi: 10.1002/pbc.28547
  • Varying presentations and favourable outcomes of COVID-19 infection in children and young adults with sickle cell disease: an additional case series with comparisons to published cases. Appiah-Kubi A, Acharya S, Fein Levy C, et al. Br J Haematol. [published online ahead of print, 2020 July 11]. doi: 10.1111/bjh.17013
  • Vulnerability of sickle cell disease persons to the COVID-19 in sub-Saharan Africa. Tonen-Wolyec S, Marini Djang’eing’a R, Kambale-Kombi P, Tshilumba CK, Bélec L, Batina-Agasa S. Hematology. 2020 Dec;25(1):280-282. doi: 10.1080/16078454.2020.1790842
  • Impact of COVID-19 infection on 24 patients with sickle cell disease. One center urban experience, Detroit, MI, USA. Balanchivadze N, Kudirka AA, Askar S, et al. Hemoglobin. [published online ahead of print, 2020 July 28]. doi: 10.1080/03630269.2020.1797775

Membranopathies (anomalies de la membrane du globule rouge)

  • COVID-19 and hereditary spherocytosis: A recipe for hemolysis. Severance TS, Rahim MQ, French J 2nd, et al. Pediatr Blood Cancer. 2020;e28548 [published online ahead of print, 2020 Jul 25]. doi: 10.1002/pbc.28548

Thalassémie

  • Challenging times for children with transfusion-dependent thalassemia amid the COVID-19 pandemic. Yadav U, Pal R. Indian Pediatr. [published online ahead of print, 2020 Apr 7]. S097475591600155
  • SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Motta I, Migone De Amicis M, Pinto VM, et al. Am J Hematol. [published online ahead of print, 2020 Apr 20]. doi: 10.1002/ajh.25840
  • Implications of SARSr-CoV 2 infection in thalassemias: do patients fall into the « high clinical risk » category? Karimi M, De Sanctis V. Acta Biomed. 2020 May 11;91(2):50-56. doi: 10.23750/abm.v91i2.9592
  • The medical concerns of patients with thalassemias at the time of COVID-19 outbreak: the personal experience and the international recommendations. Canatan D, De Sanctis V. Acta Biomed. 2020 May 11;91(2):218-221. doi: 10.23750/abm.v91i2.9533
  • Prevalence and mortality due to outbreak of novel coronavirus disease (COVID-19) in β-thalassemias: the nationwide Iranian experience. Karimi M, Haghpanah S, Azarkeivan A, et al. Br J Haematol. [published online ahead of print, 2020 June 2]. doi: 10.1111/bjh.16911
  • Thalassemic child presenting with anosmia due to COVID-19. Marhaeni W, Wijaya AB, Kusumaningtyas P, Mapianto RS. Indian J Pedriatr. [published online ahead of print, 2020 June 9]. doi: 10.1007/s12098-020-03370-4
  • COVID-19 in a Patient with β-Thalassemia Major and Severe Pulmonary Arterial Hypertension. Pinto VM, Derchi GE, Bacigalupo L, Pontali E, Forni GL. Hemoglobin. [published online ahead of print, 2020 June 18]. doi: 10.1080/03630269.2020.1779082
  • COVID‐19 and thalassaemia: A position statement of the Thalassaemia International Federation. Farmakis D, Giakoumis A, Cannon L, Angastiniotis M, Eleftheriou A. Eur J Haematol. [published online ahead of print, 2020 June 23]. doi: 10.1111/ejh.13476
  • Impact of SARS CoV-2 in hemoglobinopathies with immune disfunction and epidemiology. A protective mechanism from beta chain hemoglobin defects? Torti L, Maffei L, Sorrentino F, De Fabritiis P, Miceli R, Abruzzese E. Mediterr J Hematol Infect Dis. 2020 Jul 1;12(1):e2020052. doi: 10.4084/MJHID.2020.052